Navigating copay accumulators in the health insurance maze

Eyeing the practice that negates some savings of treatment assistance cards

‘Tis that season again — not the one adorned with festive decorations and holiday cheer, but the one with the formidable task of selecting a health insurance plan from the marketplace at healthcare.gov. For those contending with hemophilia or other chronic health conditions, this annual ritual can be a precarious walk on a financial tightrope.

This year, copay accumulators have come to the forefront of my awareness. I’d heard the term, but it wasn’t until my 2023 plan had such a program that I realized how it affected my pocketbook. It’s no joke.

My home state of Florida, unfortunately, allows copay accumulators. That’s bad news for me.

My health plan

My 2023 plan, from Florida Blue, has a high-deductible Health Savings Account (HSA), which lets me set aside money on a pretax basis to pay for qualified medical expenses. Florida Blue is my county’s best option for a person with hemophilia, as it covers my medications.

However, the plan makes me confront sobering figures. A $6,800 yearly deductible accompanies my monthly premium of $565.61. While that’s undeniably a substantial financial commitment, being uninsured is even more daunting, considering the expenses involved with my hemophilia B and von Willebrand disease.

The two medications critical to my health bear a substantial price tag — over $7,000 per dose. And I frequently need multiple doses, given the nature of my bleeding disorders. Copay assistance cards from drug manufacturers and grants from the Pan Foundation alleviate some of my financial burden. But shockingly, my insurance company pocketed the copay assistance that I received this year.

How a copay accumulator works

Let’s look at my insurance plan, for example, with its annual $6,800 deductible. For simplicity, let’s say I also have a $5,000 copay assistance card or coupon that I’ll want to use to refill my medication, which we’ll say costs $5,000.

Without a copay accumulator, that $5,000 coupon will count toward my annual deductible. $6,800 — $5,000 = $1,800. I’m responsible for only that $1,800 to reach my deductible.

With a plan that has a copay accumulator, however, I lose money because the $5,000 coupon won’t count toward my deductible. $6,800 — $0 = $6,800. I have to pay the full $6,800 before satisfying my plan’s deductible.

Where does that coupon money, generally from the drug manufacturer, go instead? To my insurer. Meanwhile, I’m burdened with additional out-of-pocket expenses.

It’s a system that grants insurance companies the leeway to double-dip into my pocket, which I find unjust and counterintuitive.

The fight against the practice According to The AIDS Institute, Arizona, Arkansas, Connecticut, Delaware, Georgia, Illinois, Kentucky, Louisiana, Maine, New York, North Carolina, Oklahoma, Puerto Rico, Tennessee, Virginia, Washington, and West Virginia prohibited copay accumulators on marketplace plans in 2023. That’s the good news for patients. The institute also has a “report card” for each state regarding its copay accumulators.

If you’d like to help stop this practice, you can email your legislators here to encourage them to support the HELP Copays Act. The National Bleeding Disorders Foundation collects recent developments on copay accumulators and the hemophilia community on its website.

©Jennifer Lynne, 2024, All rights reserved

Jennifer Lynne

Jennifer is an entrepreneur specializing in digital marketing, a self-professed computer nerd, and a nationally competitive Scrabble player. Jennifer has strong ties to the bleeding disorder community; she was diagnosed in 1975 with hemophilia B and Von Willebrand’s disease at age 10.

She is a graduate of the University of Wisconsin, Madison with a BA in marketing and journalism, and MIT’s Birthing of Giants Fellowship Program. A native of Brookfield, Wisconsin, she now resides in sunny Punta Gorda, Florida. Jennifer hopes that her column will raise awareness for hemophilia and other bleeding disorders, especially among women.

Previous
Previous

Genetic testing raises questions about my bleeding disorders

Next
Next

What I learned from a recent summit on mild bleeding disorders